

Special Issue

Liver Inflammation and Hepato-Pancreatic Biliary Cancers (HPBCs)

Message from the Guest Editor

Chronic hepatitis virus infection (hepatitis B virus, HBV; hepatitis C virus, HCV) causes chronic inflammation in the liver, which greatly increases the risk of developing liver cancer (HCC). Chronic hepatitis infection causes genetic mutations in hepatocytes that progress to cancer via cirrhosis, as the latter causes liver cell fibrosis and promotes cancer development. There is also epidemiological evidence of chronic hepatitis inflammation increasing the risk of biliary tract cancers. For hepatitis and pancreatic cancer, common risk factors (e.g., alcohol consumption and obesity) have also been reported to increase risk. We would like to provide an update on the associations between liver inflammation and hepato-pancreatic biliary cancers (HPBCs) from epidemiological, clinical, and basic medical aspects.

Guest Editor

Prof. Dr. Tsutomu Masaki
Department of Gastroenterology, Kagawa Saiseikai Hospital,
Takamatsu, Japan

Deadline for manuscript submissions

closed (31 July 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/223935

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)